Figure-3

Figure 3. Dupilumab significantly improved EASI-75 response at 16 weeks and maintained the improvement through 52 weeks in children aged 6–11 years with AD34,35

Figure 3. Dupilumab significantly improved EASI-75 response at 16 weeks and maintained the improvement through 52 weeks in children aged
6–11 years with AD34,35

Figure 3. Dupilumab significantly improved EASI-75 response at 16 weeks and maintained the improvement through 52 weeks in children aged
6–11 years with AD34,35